Fc fragment of IgM receptor (FCMR) (FCMR)

The Fc fragment of IgM receptor (FCMR), historically known as FAIM3 or TOSO, is a type I transmembrane sialoglycoprotein primarily expressed on the surface of B-lymphocytes and, to a lesser extent, on T-cells and NK cells [1, 2]. It serves as the high-affinity receptor for the Fc portion of IgM, the first antibody isotype produced during an immune response, and is essential for maintaining IgM homeostasis [3]. FCMR facilitates the endocytosis of IgM-antigen complexes, thereby regulating B-cell receptor (BCR) signaling and the threshold for B-cell activation [4]. In clinical oncology, FCMR is significantly overexpressed in chronic lymphocytic leukemia (CLL) cells compared to healthy B-cells, which correlates with disease progression and resistance to apoptosis [5]. This overexpression makes FCMR a promising biomarker for the diagnosis and prognosis of B-cell malignancies [6]. Although initially named FAIM3 due to its perceived role in inhibiting Fas-mediated apoptosis, its primary physiological function is now recognized as the regulation of humoral immunity through IgM interaction [1, 3]. Therapeutic strategies targeting FCMR, such as monoclonal antibodies, are being explored to induce antibody-dependent cellular cytotoxicity (ADCC) in malignant B-cells while sparing other immune populations [5, 6]. However, targeting this receptor carries the risk of disrupting normal IgM-mediated immune responses and potentially causing hypogammaglobulinemia [3]. Overall, FCMR represents a specialized immune receptor with significant implications for both normal B-cell biology and the treatment of hematological cancers.

Other names

FAIM3TOSOFas apoptotic inhibitory molecule 3IgM Fc receptorFc-mu receptor

Induction of antibody-dependent cellular cytotoxicity (ADCC) and modulation of IgM-mediated survival signaling pathways [5, 6].